{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:02:38Z","timestamp":1790877758141,"version":"4.1.0"},"reference-count":57,"publisher":"BMJ","funder":[{"name":"Hubei Provincial Outstanding Young Talent Project for Public Health","award":["220171414"],"award-info":[{"award-number":["220171414"]}]},{"DOI":"10.13039\/501100007046","name":"Wuhan University","doi-asserted-by":"publisher","award":["670100029"],"award-info":[{"award-number":["670100029"]}],"id":[{"id":"10.13039\/501100007046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ EBM"],"accepted":{"date-parts":[[2026,9,16]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis evaluate the clinical effectiveness, safety and potential risk compensation associated with oral pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase and the Cochrane Library up to 17 September 2025 for randomised controlled trials (RCTs) and observational studies. The primary outcomes were HIV incidence and sexually transmitted infections (STIs). Secondary outcomes included PrEP adherence and adverse events. Meta-analyses used random-effects models, presenting results as relative risks (RRs), risk differences and calculated absolute risk reduction\/increase (ARR\/ARI) and number needed to treat (NNT) where applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 21 studies (7 RCTs and 14 observational) with 18\u2009214 participants were included. PrEP use was associated with a 68% RR reduction in HIV acquisition (RR=0.32, 95%\u2009CI 0.19 to 0.53; ARR=1.14%, NNT=88). High adherence (\u226580%) led to a 78% reduction in HIV risk (RR=0.22, 95%\u2009CI 0.09 to 0.54; ARR=1.51%, NNT=66), while lower adherence showed a non-significant 58% reduction (RR=0.42, 95%\u2009CI 0.16 to 1.09). Meta-regression indicated a 17% decrease in efficacy per 10% drop in adherence (\u03b2 = \u20131.7, p=0.009). No significant differences were found in any adverse events (RR=1.02, 95%\u2009CI 0.88 to 1.18)\u2009or serious adverse events (RR=0.93, 95%\u2009CI 0.68 to 1.28; ARI=\u22120.00%). There was no significant increase in overall STIs (RR=1.05, 95%\u2009CI 0.95 to 1.17; ARI=0.05%) or syphilis incidence (RR=1.11, 95%\u2009CI 0.96 to 1.30; ARI=0.11%). Sexual behaviour outcomes were mixed, with no consistent evidence of increased risk-taking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PrEP effectively reduces HIV incidence among MSM, particularly when adherence is high, without a significant increase in overall STIs risk. Adherence support and comprehensive sexual health counselling should be integral to PrEP programmes to maximise its effectiveness and mitigate potential risk compensation behaviours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024593380.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjebm-2025-113648","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:25:46Z","timestamp":1790875546000},"page":"bmjebm-2025-113648","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness, safety, adherence and risk compensation of oral pre-exposure prophylaxis (PrEP) in men who have sex with men: a systematic review and meta-analysis"],"prefix":"10.1136","author":[{"given":"Chengchang","family":"Xiao","sequence":"first","affiliation":[{"name":"Wuhan City University Wuhan, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4350-6911","authenticated-orcid":false,"given":"Kecheng","family":"Qu","sequence":"additional","affiliation":[{"name":"Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[{"name":"Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingya","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxi","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department for AIDS Control and Prevention, Wuhan Center for Disease Control and Prevention, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9538-5590","authenticated-orcid":false,"given":"Songjie","family":"Wu","sequence":"additional","affiliation":[{"name":"Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[{"name":"Wuhan University, Wuhan, Hubei, China"},{"name":"Department of Epidemiology and Health Statistics, Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026100110201892000_bmjebm-2025-113648v1.1","unstructured":"WHO . HIV\/AIDS fact sheet. 2023. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids [Accessed 24 Sep 2024]."},{"key":"2026100110201892000_bmjebm-2025-113648v1.2","unstructured":"WHO . Global HIV, hepatitis and STIs programmes. 2023. Available: http:\/\/tinyurl.com\/yckavejf [Accessed 05 Sep 2024]."},{"key":"2026100110201892000_bmjebm-2025-113648v1.3","unstructured":"UNAIDS . Global HIV & AIDS statistics- fact sheet. 2023. Available: https:\/\/www.unaids.org\/en\/resources\/fact-sheet [Accessed 05 Sep 2024]."},{"key":"2026100110201892000_bmjebm-2025-113648v1.4","unstructured":"WHO . HIV\/AIDS surveillance in Europe: 2022 - 2021 data. 2022. Available: https:\/\/www.who.int\/europe\/publications\/i\/item\/9789289058636 [Accessed 05 Sep 2024]."},{"key":"2026100110201892000_bmjebm-2025-113648v1.5","unstructured":"CDC . Diagnoses of HIV infection in the United States and dependent areas 2020: special focus profiles. Available: http:\/\/tinyurl.com\/3z3uadfd [Accessed 10 Sep 2024]."},{"key":"2026100110201892000_bmjebm-2025-113648v1.6","unstructured":"CDC . HIV in the United States and dependent areas. 2022. Available: https:\/\/www.cdc.gov\/hiv\/statistics\/overview\/ataglance.html [Accessed 05 Sep 2024]."},{"key":"2026100110201892000_bmjebm-2025-113648v1.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.9865"},{"key":"2026100110201892000_bmjebm-2025-113648v1.8","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","article-title":"Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2022","journal-title":"Lancet HIV"},{"key":"2026100110201892000_bmjebm-2025-113648v1.9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy182"},{"key":"2026100110201892000_bmjebm-2025-113648v1.10","unstructured":"Training C . Cochrane handbook for systematic reviews of interventions. 2023. Available: https:\/\/training.cochrane.org\/handbook"},{"key":"2026100110201892000_bmjebm-2025-113648v1.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026100110201892000_bmjebm-2025-113648v1.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"2026100110201892000_bmjebm-2025-113648v1.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026100110201892000_bmjebm-2025-113648v1.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026100110201892000_bmjebm-2025-113648v1.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026100110201892000_bmjebm-2025-113648v1.16","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000733"},{"key":"2026100110201892000_bmjebm-2025-113648v1.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.19.1690"},{"key":"2026100110201892000_bmjebm-2025-113648v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2017.05.049"},{"key":"2026100110201892000_bmjebm-2025-113648v1.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048478","article-title":"Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations","volume":"12","author":"O Murchu","year":"2022","journal-title":"BMJ Open"},{"key":"2026100110201892000_bmjebm-2025-113648v1.20","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000002640"},{"key":"2026100110201892000_bmjebm-2025-113648v1.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2026100110201892000_bmjebm-2025-113648v1.22","doi-asserted-by":"publisher","DOI":"10.2307\/2669529"},{"key":"2026100110201892000_bmjebm-2025-113648v1.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2026100110201892000_bmjebm-2025-113648v1.24","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182801081"},{"key":"2026100110201892000_bmjebm-2025-113648v1.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"2026100110201892000_bmjebm-2025-113648v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00056-2"},{"key":"2026100110201892000_bmjebm-2025-113648v1.27","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31828ece33"},{"key":"2026100110201892000_bmjebm-2025-113648v1.28","doi-asserted-by":"crossref","DOI":"10.2196\/71494","article-title":"Tenofovir to Prevent HIV Infection in Western China: Pragmatic Randomized Controlled Trial","volume":"11","author":"Tao","year":"2025","journal-title":"JMIR Public Health Surveill"},{"key":"2026100110201892000_bmjebm-2025-113648v1.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033103","article-title":"Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers","volume":"7","author":"Mutua","year":"2012","journal-title":"PLoS ONE"},{"key":"2026100110201892000_bmjebm-2025-113648v1.30","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S2352-3018(19)30341-8","article-title":"On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial","volume":"7","author":"Antoni","year":"2020","journal-title":"Lancet HIV"},{"key":"2026100110201892000_bmjebm-2025-113648v1.31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/QAI.0000000000002107","article-title":"HIV Seroconversion in the Era of Pharmacologic Prevention: A Case-Control Study at a San Francisco STD Clinic","volume":"82","author":"Johnson","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026100110201892000_bmjebm-2025-113648v1.32","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jiac.2022.02.013","article-title":"A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo","volume":"28","author":"Mizushima","year":"2022","journal-title":"J Infect Chemother"},{"key":"2026100110201892000_bmjebm-2025-113648v1.33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48782","article-title":"Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial","volume":"5","author":"Wang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026100110201892000_bmjebm-2025-113648v1.34","doi-asserted-by":"crossref","unstructured":"Streeck H , Jansen K , Crowell TA , et al . HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019. Eurosurveillance 2022;27. doi:10.2807\/1560-7917.ES.2022.27.14.2100591","DOI":"10.2807\/1560-7917.ES.2022.27.14.2100591"},{"key":"2026100110201892000_bmjebm-2025-113648v1.35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.30806","article-title":"Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men","volume":"3","author":"McManus","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026100110201892000_bmjebm-2025-113648v1.36","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001885"},{"key":"2026100110201892000_bmjebm-2025-113648v1.37","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/OLQ.0000000000001424","article-title":"Recurrent Sexually Transmitted Infections Among a Cohort of Men Who Have Sex With Men Using Preexposure Prophylaxis in Belgium Are Highly Associated With Sexualized Drug Use","volume":"48","author":"De Baetselier","year":"2021","journal-title":"Sex Transm Dis"},{"key":"2026100110201892000_bmjebm-2025-113648v1.38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245925","article-title":"Low use of condom and high STI incidence among men who have sex with men in PrEP programs","volume":"16","author":"Ayerdi Aguirrebengoa","year":"2021","journal-title":"PLoS ONE"},{"key":"2026100110201892000_bmjebm-2025-113648v1.39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/09540121.2019.1620167","article-title":"Misclassification of sexual health risks in a self-identified low risk cohort of men who have sex with men (MSM) enrolled in a community based PrEP program","volume":"32","author":"Freeborn","year":"2020","journal-title":"AIDS Care"},{"key":"2026100110201892000_bmjebm-2025-113648v1.40","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2252-9"},{"key":"2026100110201892000_bmjebm-2025-113648v1.41","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3018(19)30136-5","article-title":"Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study","volume":"6","author":"Hoornenborg","year":"2019","journal-title":"Lancet HIV"},{"key":"2026100110201892000_bmjebm-2025-113648v1.42","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001718"},{"key":"2026100110201892000_bmjebm-2025-113648v1.43","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2017-053377"},{"key":"2026100110201892000_bmjebm-2025-113648v1.44","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26312","article-title":"Factors associated with PrEP-era HIV seroconversion in a 4-year U.S. national cohort of n = 6059 sexual and gender minority individuals who have sex with men, 2017-2022","volume":"27","author":"Grov","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2026100110201892000_bmjebm-2025-113648v1.45","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001145"},{"key":"2026100110201892000_bmjebm-2025-113648v1.46","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003837"},{"key":"2026100110201892000_bmjebm-2025-113648v1.47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2591"},{"key":"2026100110201892000_bmjebm-2025-113648v1.48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/apc.2024.0083","article-title":"Patient and Provider Perceptions of Barriers and Facilitators to Pre-exposure Prophylaxis Access and Adherence in Black and Latinx Young Men Who Have Sex with Men","volume":"38","author":"Ribas Rietti Souto","year":"2024","journal-title":"AIDS Patient Care STDS"},{"key":"2026100110201892000_bmjebm-2025-113648v1.49","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10508-023-02776-3","article-title":"Sexual Identity Development and Social Ecological Facilitators and Barriers of PrEP Uptake and Adherence Among Latinx Men Who Have Sex with Men","volume":"53","author":"Dillon","year":"2024","journal-title":"Arch Sex Behav"},{"key":"2026100110201892000_bmjebm-2025-113648v1.50","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-024-17854-x","article-title":"Trajectories of anxiety and depression among Chinese men who have sex with men on pre-exposure prophylaxis: a group-based trajectory model approach","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Public Health"},{"key":"2026100110201892000_bmjebm-2025-113648v1.51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11904-016-0308-x","article-title":"Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings","volume":"13","author":"Marcus","year":"2016","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026100110201892000_bmjebm-2025-113648v1.52","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae569","article-title":"Trajectories of Adherence to Oral Pre-exposure Prophylaxis and Risks of HIV and Sexually Transmitted Infections","volume":"11","author":"Unigwe","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026100110201892000_bmjebm-2025-113648v1.53","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S2468-2667(22)00106-2","article-title":"Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study","volume":"7","author":"Jourdain","year":"2022","journal-title":"Lancet Public Health"},{"key":"2026100110201892000_bmjebm-2025-113648v1.54","article-title":"Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate\/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083","volume":"18","author":"Mitchell","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2026100110201892000_bmjebm-2025-113648v1.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2021.04.036"},{"key":"2026100110201892000_bmjebm-2025-113648v1.56","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ324"},{"key":"2026100110201892000_bmjebm-2025-113648v1.57","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-023-00666-w"}],"container-title":["BMJ Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjebm-2025-113648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:25:52Z","timestamp":1790875552000},"score":1,"resource":{"primary":{"URL":"https:\/\/ebm.bmj.com\/lookup\/doi\/10.1136\/bmjebm-2025-113648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":57,"alternative-id":["10.1136\/bmjebm-2025-113648"],"URL":"https:\/\/doi.org\/10.1136\/bmjebm-2025-113648","relation":{},"ISSN":["2515-446X","2515-4478"],"issn-type":[{"value":"2515-446X","type":"print"},{"value":"2515-4478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}